News | Guidewires | May 06, 2024

Teleflex Announces the Limited Market Release of the Wattson Temporary Pacing Guidewire

Company expands structural heart portfolio and begins the limited market release of a bipolar temporary pacing guidewire intended to introduce and position catheters and other interventional devices within the chambers of the heart while transmitting an electrical signal from an external pulse generator to the heart

Company expands structural heart portfolio and begins the limited market release of a bipolar temporary pacing guidewire

May 6, 2024 — Teleflex Incorporate, a leading global provider of medical technologies, today announced that the Wattson Temporary Pacing Guidewire limited market release has commenced at Columbia University Irving Medical Center. The first cases were performed by Dr. Tamim Nazif, Director of Clinical Research, Dr. Susheel Kodali, Professor of Medicine and Director of the Structural Heart and Valve Center, and Dr. Isaac George, Surgical Director of the Heart Valve Center.

Featuring a simple design to create procedural efficiencies, the Wattson Temporary Pacing Guidewire offers dual functionality, supporting both valve delivery and ventricular bipolar pacing during structural heart procedures, including transcatheter aortic valve replacement (TAVR) and balloon aortic valvuloplasty (BAV). The device offers a procedural alternative designed to avoid potential complications1, steps1, and costs2 associated with traditional right ventricular pacing. From its flexible distal pigtail shape to its multiple electrode, bipolar design, the Wattson™ Temporary Pacing Guidewire is engineered to help reduce the risk of ventricular perforation while providing confidence in capture during rapid pacing.

“We are thrilled that our team at Columbia University Irving Medical Center was selected for the Wattson Temporary Pacing Guidewire limited market release and are proud to have completed the first TAVR procedures with this important new device,” said Dr. Tamim Nazif, Director of Clinical Research for Columbia Interventional Cardiovascular Care, Director of the Interventional Cardiology Fellowship Program, and assistant professor in medicine at Columbia University Irving Medical Center. “The Wattson Temporary Pacing Guidewire facilitated minimalist TAVR procedures with safe and reliable LV pacing throughout our first two days of cases, and we are eager to continue to use it moving forward.”

Teleflex received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Wattson Temporary Pacing Guidewire in May of 2023.

“Providing interventionalists with a new tool specifically engineered to address unmet clinical needs frequently encountered during structural heart procedures is a significant milestone for Teleflex,” said Roger Graham, President and General Manager of the Teleflex Interventional business unit. “The Wattson Temporary Pacing Guidewire reflects our steadfast focus on filling gaps in existing technologies as well as our commitment to providing more options that further simplify minimalist TAVR and other structural procedures.”

For more information: www.teleflex.com

 

References:

  1. Clinical Investigation: TEMPORARY PACING GUIDEWIRE STUDY. Testing completed by Teleflex. Data on file with Teleflex. Bench test results may not necessarily be indicative of clinical performance.
  2. Faurie B, Souteyrand G, Staat P, Godin M, Caussin C, Van Belle E, Mangin L, Meyer P, Dumonteil N, Abdellaoui M, Monségu J, Durand-Zaleski I, Lefèvre T; EASY TAVI Investigators. Left Ventricular Rapid Pacing Via the Valve Delivery Guidewire in Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2019 Dec 23;12(24):2449-2459.

 


Related Content

News | Structural Heart

April 25, 2024 — Atlantic Health System’s Morristown Medical Center treated the first patient in New Jersey using ...

Home April 25, 2024
Home
News | Structural Heart

April 9, 2024 — UC Davis Health cardiology team members are among the first in the country to treat patients with ...

Home April 09, 2024
Home
News | Structural Heart

March 25, 2024 — In a groundbreaking medical advancement, three esteemed cardiologists from CLS Health, Dr. Bahaeddin ...

Home March 25, 2024
Home
News | Structural Heart

March 12, 2024 — Medtronic plc, a global leader in healthcare technology, today announced two late-breaking data ...

Home March 12, 2024
Home
News | Structural Heart

February 20, 2024 — As New Jersey’s leading provider of high-quality cardiac procedures and diagnostic testing and an ...

Home February 20, 2024
Home
News | Structural Heart

February 15, 2024 — Abbott announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee ...

Home February 15, 2024
Home
News | Structural Heart

February 9, 2024 — Physicians in the Smidt Heart Institute at Cedars-Sinai have achieved two significant firsts ...

Home February 09, 2024
Home
News | Structural Heart

January 4, 2024 — Laguna Tech USA, a privately-held medical technology company dedicated to innovations in structural ...

Home January 04, 2024
Home
News | Structural Heart

December 12, 2023 — Think of them as the Energizer Bunnies of the heart, tiny natural batteries that keep this vital ...

Home December 12, 2023
Home
News | Structural Heart

October 31, 2023 — Edwards Lifesciences Corporation announced one-year results from CLASP IID, the first randomized ...

Home October 31, 2023
Home
Subscribe Now